Company intelligence / Profile preview

CardioNavi MedTech

Wuhan, Hubei, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

CardioNavi MedTech is developing innovative structural heart devices, with a focus on mitral valve replacement. The company has recently expanded its R&D capabilities with a new center in Shanghai dedicated to advancing these technologies. No published clinical results are available yet as of June 2025.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

No major external pharmaceutical or biotech partnerships publicly disclosed; operates within Grand Pharma’s network of subsidiaries and R&D centers

Beyond the preview

Go deeper on CardioNavi MedTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioNavi MedTech.

Explore the full profile